ArticleEmerging infectious diseases2022
Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic.
Article in Emerging infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07167173 (Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis), which is not on this map. Cited by 65 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictive Model for Multidrug Resistance in Patients Admitted to the Emergency Department With Sepsis
Who cites it
65 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review.BMJ global health · 2024Pooled it
- Systematic Review and Meta-analysis of Deaths Attributable to Antimicrobial Resistance, Latin America.Emerging infectious diseases · 2023Pooled it
- Infection outbreaks caused by carbapenemase-producing Enterobacterales: An epidemiological surveillance study in public hospitals in Chile, 2017-2024.Global epidemiology · 2026Article
- Article
- Trends and drivers of multidrug-resistant bacteria incidence in 59 Chilean intensive care units, 2015-2024: a Bayesian hierarchical analysis.Lancet regional health. Americas · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Incidence of colonization and infection with carbapenemase-producing Enterobacterales in Toronto and Peel Region, Ontario, 2007-2024.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2026Article
- Comparative outcomes of ceftazidime-avibactam versus meropenem-vaborbactam for KPC-producing Enterobacterales infections.Antimicrobial agents and chemotherapy · 2026Article
- Expanding Threat of Carbapenemase-ProducingbioRxiv : the preprint server for biology · 2026Article
- Prevalence and phenotypic characterization of carbapenem resistance in multidrug-resistant Gram-negative bacteria across selected healthcare facilities in the United Arab Emirates: a retrospective study.BMC infectious diseases · 2026Article
- Epidemiological Insights into Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Prevalence of Carbapenem-Resistant Gram-Negative Bacilli from Intensive Care Units from Latin America and the Caribbean: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- Epidemiological and Clinical Characteristics Associated with Antimicrobial-Resistant Urinary Tract Infections in Outpatient and Inpatient Settings: A Retrospective Study from Northwestern Mexico.Pathogens (Basel, Switzerland) · 2026Article
- The Caribbean under the radar? A scoping review of carbapenemase-producing Enterobacterales across the region.PLOS global public health · 2026Article
- Article
- First nationwide survey onAntimicrobial agents and chemotherapy · 2025Article
- Molecular detection of carbapenemases in critical microorganisms since the onset of the COVID-19 pandemic in Peru.JAC-antimicrobial resistance · 2025Article
- Thirty-Day Mortality Associated With Carbapenemase-ProducingOpen forum infectious diseases · 2025Article
- Molecular characterization of blaBMC infectious diseases · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During 2020-2021, countries in Latin America and the Caribbean reported clinical emergence of carbapenemase-producing Enterobacterales that had not been previously characterized locally, increased prevalence of carbapenemases that had previously been detected, and co-production of multiple carbapenemases in some isolates. These increases were likely fueled by changes related to the COVID-19 pandemic, including empirical antibiotic use for potential COVID-19-related bacterial infections and healthcare limitations resulting from the rapid rise in COVID-19 cases. Strengthening antimicrobial resistance surveillance, epidemiologic research, and infection prevention and control programs and antimicrobial stewardship in clinical settings can help prevent emergence and transmission of carbapenemase-producing Enterobacterales.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.